Interleukin-7 enhances the in vivo anti-tumor activity of tumor-reactive CD8+ T cells with induction of IFN-gamma in a murine breast cancer model

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 265-271

  Yuan, Chun Hui ^a   Yang, Xue Qin ^b   Zhu, Cheng Liang ^c   Liu, Shao Ping ^d   Wang, Bi Cheng ^a   Wang, Fu Bing ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b JINGCHU UNIVERSITY OF TECHNOLOGY   (China)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^d Hubei Cancer Clinical Study Center   (China)

Author keywords

Anti tumor activity; Breast cancer; IFN ; Interleukin 7

Indexed keywords

ANTIBODY; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 7;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; BREAST TUMOR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; FEMALE; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; PLASMID; SECRETION (PROCESS);

ANIMALS; ANTIBODIES; ANTIGENS, CD8; BREAST NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENETIC VECTORS; INTERFERON-GAMMA; INTERLEUKIN-7; MICE; MICE, INBRED BALB C; PLASMIDS;

EID: 84894071527     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.265     Document Type: Article

References (36)

1. Anderson RJ, Schneider J (2007). Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine, 25, B24-34.
2. Andersson A, Yang SC, Huang M, et al (2009). IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol, 182, 6951-8.
3. Appasamy PM (1999). Biological and clinical implications of interleukin-7 and lymphopoiesis. Cytokines Cell Mol Ther, 5, 25-39.
4. Ferrari G, King K, Rathbun K, et al (1995). IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). Clin Exp Immunol, 101, 239-48.
5. Finke S, Trojaneck B, Lefterova P, et al (1998). Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Ther, 5, 31-9.
6. Fry TJ, Mackall CL (2002). Interleukin-7: from bench to clinic. Blood, 99, 3892-904.
7. Geiselhart LA, Humphries CA, Gregorio TA, et al (2001). IL-7 administration alters the CD4:CD8 ratio, increases T cell numbers, and increases T cell function in the absence of activation. J Immunol, 166, 3019-27.
8. Jicha DL, Mule JJ, Rosenberg SA (1991). Interleukin-7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med, 174, 1511-5.
9. + T cells. PNAS, 101, 1969-74.
10. + T-cell memory in tumor immunology and immunotherapy. Immunol Rev, 211, 214-24.
11. Krawczenko A, Kieda C and Duś D (2005). The biological role and potential therapeutic application of interleukin-7. Arch Immunol Ther Exp (Warsz), 53, 518-25.
12. Lai L, Jin J, Goldschneider I (2011). In vivo antitumor activity of a recombinant IL-7/HGFbeta hybrid cytokine in mice. Cancer Res, 71, 61-7.
13. Lee S, Margolin K (2011). Cytokines in cancer immunotherapy. Cancers, 3, 3856-93.
14. Li B, VanRoey MJ, Jooss K (2007). Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy. Clin Immunol, 123, 155-65.
15. Liu S, Lizee G, Lou Y, et al (2007). IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol, 19, 1213-21.
16. Lo CH, Lee SC, Wu PY, et al (2003). Antitumor and antimetastatic activity of IL-23. J Immunol, 171, 600-7.
17. Lundstrom W, Fewkes NM, Mackall CL (2012). IL-7 in human health and disease. Semin Immunol, 24, 218-24.
18. Lynch DH, Miller RE (1994). Interleukin-7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J Exp Med, 179, 31-42.
19. Murphy WJ, Back TC, Conlon KC, et al (1993). Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. J Clin Invest, 92, 1918-24.
20. Pellegrini M, Calzascia T, Elford AR, et al (2009). Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med, 15, 528-36.
21. Pellegrini M, Calzascia T, Toe JG, et al (2011). IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell, 144, 601-13.
22. Pellegrini M, Mak TW (2010). Tumor immune therapy: lessons from infection and implications for cancer-can IL-7 help overcome immune inhibitory networks? Eur J Immunol, 40, 1852-61.
23. Roato I, Brunetti G, Gorassini E, et al (2006). IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. PLoS One, 1, e124.
24. + cells but a relative decrease of CD4+ T-regulatory cells. J Immunother, 29, 313-9.
25. Rubinstein MP, Lind NA, Purton JF, et al (2008). IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response. Blood, 112, 3704-12.
26. Sharma S, Batra RK, Yang SC, et al (2003). Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Hum Gene Ther, 14, 1511-24.
27. Sharma S, Wang J, Huang M, et al (1996). Interleukin-7 gene transfer in non-small-cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances antitumor reactivity. Cancer Gene Ther, 3, 302-13.
28. Strengell M, Matikainen S, Siren J, et al (2003). IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol, 170, 5464-9.
29. Tanaka H, Yoshizawa H, Yamaguchi Y, et al (1999). Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. J Immunol, 162, 3574-82.
30. Terabe M, Park JM, Berzofsky JA (2004). Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother, 53, 79-85.
31. Unsinger J, McGlynn M, Kasten KR, et al (2010). IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol, 184, 3768-79.
32. Verhoeyen E, Dardalhon V, Ducrey-Rundquist O, et al (2003). IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood, 101, 2167-74.
33. Vudattu NK, Magalhaes I, Schmidt M, et al (2007). Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer. Int J Cancer, 121, 1512-9.
34. Wu B, Shen RN, Wang WX, et al (1993). Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells. Stem Cells, 11, 412-21.
35. Yang H, Spencer AU, Teitelbaum DH (2005). Interleukin-7 administration alters intestinal intraepithelial lymphocyte phenotype and function in vivo. Cytokine, 31, 419-28.
36. Zaidi MR, Merlino G (2011). The two faces of interferon-gamma in cancer. Clin Cancer Res, 17, 6118-24.